KRAS Mutation Detection in Blood for Colorectal Cancer Treatment
Author Information
Author(s): Fiore F Di, Charbonnier F, Lefebure B, Laurent M, Pessot F Le, Michel P, Frebourg T
Primary Institution: University Hospital, Rouen, France
Hypothesis
Detection of KRAS mutations in blood may have clinical interest for anti-EGFR therapies in metastatic colorectal cancer.
Conclusion
Routine KRAS genotyping in blood could improve treatment strategies for metastatic colorectal cancer patients.
Supporting Evidence
- KRAS mutation is highly predictive of treatment resistance in metastatic colorectal cancer.
- Detection of KRAS mutations in blood may provide a non-invasive alternative to tumor sampling.
- Hypermethylated RASSF2 gene is frequently detected in colorectal cancer.
Takeaway
Doctors can check for a specific gene change in the blood of cancer patients to see if a treatment will work better.
Methodology
The study involved analyzing blood samples for KRAS mutations and hypermethylated DNA in patients undergoing treatment.
Limitations
Obtaining suitable tumor samples for analysis may be difficult, and the absence of mutations in primary tumors does not rule out mutations in metastases.
Participant Demographics
Patients with metastatic colorectal cancer, including a 67-year-old man and a 76-year-old man.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website